Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer

Given the company’s popularity among hedge funds and the bullish sentiment surrounding it, Tempus AI, Inc. (NASDAQ:TEM) makes it to our list of the Top 10 AI Infrastructure Stocks to Buy Now.

On July 10, 2025, Tempus AI, Inc. (NASDAQ:TEM) announced an update about its strategic partnership with Personalis. Under this expansion, the company added colorectal cancer to its existing commercialization agreement. This new agreement grants Tempus AI, Inc. (NASDAQ:TEM) exclusive rights to market its NeXT Personal Minimum Residual Disease (MRD) test across four oncology types through 2028. This follows the results from the VICTORI study, which showed early detection strength in CRC, which is crucial for timely treatment.

This agreement follows a period of strong momentum, where Tempus AI, Inc. (NASDAQ:TEM) reported a 75% increase in its revenue ($255.7 million) for Q1 2025. With strong profitability, the company has raised its full-year revenue guidance to $1.25 billion, having signed a $200 million data license deal with AstraZeneca and Pathos that will enhance AI model development in oncology.

Catering to over 50% of U.S. oncologists, Tempus AI, Inc. (NASDAQ:TEM) offers platforms like Insights, Lens, and Hub that combine sequencing diagnostics with algorithmic tools, powering data-driven cancer treatment decisions.

While we acknowledge the potential of TEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Billionaire Kerr Neilson’s 10 Stock Picks with Huge Upside Potential and Growth Stock Portfolio: 12 Companies with At Least 30% Annual Growth Rates.

Disclosure: None.